Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized...

Descripción completa

Detalles Bibliográficos
Autores principales: Fairfax, BP, Pratap, S, Roberts, ISD, Collier, J, Kaplan, R, Meade, AM, Ritchie, AW, Eisen, T, Macaulay, VM, Protheroe, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575366/
https://www.ncbi.nlm.nih.gov/pubmed/23231599
http://dx.doi.org/10.1186/1471-2407-12-590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575366/
https://www.ncbi.nlm.nih.gov/pubmed/23231599
http://dx.doi.org/10.1186/1471-2407-12-590

Ejemplares similares